SCHEMBL4482768

SCHEMBL4482768

CCN(CC)CCc1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
FLT3 P36888 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PDGFRB P09619 3/20 0.35
KIT P10721 3/20 0.35
EGFR P00533 1/20 0.35
FGFR1 P11362 1/20 0.35
NEK2 P51955 1/20 0.35
MELK Q14680 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482774 1.00 KDR (0.39) KDRPRKAA2PRKAA1KDM4EALDH1A1
SCHEMBL4494338 0.91 MAPK1 (0.42) KDRPRKAA2PRKAA1KDM4EALDH1A1
SCHEMBL4497710 0.91 MAPK1 (0.42) KDRPRKAA2PRKAA1KDM4EALDH1A1
SCHEMBL4488747 0.91 HRH3 (0.41) KDM4EALDH1A1PSEN1PSEN2APH1B
SCHEMBL4488750 0.91 HRH3 (0.41) KDM4EALDH1A1PSEN1PSEN2APH1B
SCHEMBL4505924 0.90 ACHE (0.42) KDM4EALDH1A1MEN1KMT2A
SCHEMBL4505927 0.90 ACHE (0.42) KDM4EALDH1A1MEN1KMT2A
SCHEMBL4488468 0.89 RORC (0.41) KDRPRKAA2PRKAA1MEN1KMT2A
SCHEMBL4488474 0.89 RORC (0.41) KDRPRKAA2PRKAA1MEN1KMT2A
SCHEMBL30708626 0.88 BACE1 (0.40) ALDH1A1MAOAMAOBTDP1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR KDR 1/4885PRKAA2 2282/4885PRKAA1 1738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.